Clinical trial
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00030394 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030394 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis, pharmacological study |
| Enrollment | 64 |
| Start date | Sep 1, 2002 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: